Switch theme
Sign up to access all valuation multiples
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBIÂ discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
2018
36
LTM Revenue $1.0M
LTM EBITDA n/a
$16.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HCW Biologics has a last 12-month revenue of $1.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, HCW Biologics achieved revenue of $2.6M and an EBITDA of -$27.7M.
HCW Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HCW Biologics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.8M | $2.6M | XXX | XXX | XXX |
| Gross Profit | $2.6M | $0.6M | XXX | XXX | XXX |
| Gross Margin | 91% | 22% | XXX | XXX | XXX |
| EBITDA | -$23.6M | -$27.7M | XXX | XXX | XXX |
| EBITDA Margin | -830% | -1078% | XXX | XXX | XXX |
| Net Profit | -$14.9M | -$25.0M | XXX | XXX | XXX |
| Net Margin | -524% | -974% | XXX | XXX | XXX |
| Net Debt | n/a | $2.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, HCW Biologics's stock price is $7.
HCW Biologics has current market cap of $7.9M, and EV of $16.9M.
See HCW Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.9M | $7.9M | XXX | XXX | XXX | XXX | $-30.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, HCW Biologics has market cap of $7.9M and EV of $16.9M.
HCW Biologics's trades at 17.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate HCW Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for HCW Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $16.9M | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHCW Biologics's NTM/LTM revenue growth is -100%
HCW Biologics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, HCW Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate HCW Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for HCW Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1078% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 235% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 249% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 545% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HCW Biologics acquired XXX companies to date.
Last acquisition by HCW Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . HCW Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was HCW Biologics founded? | HCW Biologics was founded in 2018. |
| Where is HCW Biologics headquartered? | HCW Biologics is headquartered in United States of America. |
| How many employees does HCW Biologics have? | As of today, HCW Biologics has 36 employees. |
| Who is the CEO of HCW Biologics? | HCW Biologics's CEO is Dr. Hing C. Wong, PhD. |
| Is HCW Biologics publicy listed? | Yes, HCW Biologics is a public company listed on NAS. |
| What is the stock symbol of HCW Biologics? | HCW Biologics trades under HCWB ticker. |
| When did HCW Biologics go public? | HCW Biologics went public in 2021. |
| Who are competitors of HCW Biologics? | Similar companies to HCW Biologics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of HCW Biologics? | HCW Biologics's current market cap is $7.9M |
| What is the current revenue of HCW Biologics? | HCW Biologics's last 12-month revenue is $1.0M. |
| What is the current EV/Revenue multiple of HCW Biologics? | Current revenue multiple of HCW Biologics is 17.7x. |
| What is the current revenue growth of HCW Biologics? | HCW Biologics revenue growth between 2023 and 2024 was -10%. |
| Is HCW Biologics profitable? | Yes, HCW Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
